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Background: Epithelial-mesenchymal transition (EMT) is known to impart metastasis and stemness characteristics
in breast cancer. To characterize the epigenetic reprogramming following Twist1-induced EMT, we characterized
the epigenetic and transcriptome landscapes using whole-genome transcriptome analysis by RNA-seq, DNA
methylation by digital restriction enzyme analysis of methylation (DREAM) and histone modifications by CHIP-seq
of H3K4me3 and H3K27me3 in immortalized human mammary epithelial cells relative to cells induced to undergo
EMT by Twist1.
Results: EMT is accompanied by focal hypermethylation and widespread global DNA hypomethylation,
predominantly within transcriptionally repressed gene bodies. At the chromatin level, the number of gene
promoters marked by H3K4me3 increases by more than one fifth; H3K27me3 undergoes dynamic genomic
redistribution characterized by loss at half of gene promoters and overall reduction of peak size by almost half. This
is paralleled by increased phosphorylation of EZH2 at serine 21. Among genes with highly altered mRNA
expression, 23.1% switch between H3K4me3 and H3K27me3 marks, and those point to the master EMT targets and
regulators CDH1, PDGFRα and ESRP1. Strikingly, Twist1 increases the number of bivalent genes by more than two
fold. Inhibition of the H3K27 methyltransferases EZH2 and EZH1, which form part of the Polycomb repressive
complex 2 (PRC2), blocks EMT and stemness properties.
Conclusions: Our findings demonstrate that the EMT program requires epigenetic remodeling by the Polycomb
and Trithorax complexes leading to increased cellular plasticity. This suggests that inhibiting epigenetic remodeling
and thus decrease plasticity will prevent EMT, and the associated breast cancer metastasis.Background
Epithelial-mesenchymal transition (EMT) is known to
promote cellular plasticity during the formation of the
mesoderm from epiblasts and the neural crest cells from
the neural tube in the developing embryo as well as during
adult wound healing [1]. During EMT, epithelial cells lose
their epithelial characteristics and acquire mesenchymal
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stated.migration. Similar to embryo development, neoplastic cells
have been shown to reactivate EMT leading to cancer me-
tastasis [2]. Induction of EMT is also involved in the de-
velopment of resistance to cytotoxic chemotherapy and
targeted agents [3-5]. In addition, EMT imparts stem cell
properties to differentiated cells [6]. Since cancer cells
seem to acquire stem cell properties dynamically in re-
sponse to the tumor microenvironment and become dif-
ferentiated at distant sites, it has been suggested that
major epigenetic remodeling would occur during EMT to
facilitate metastasis. Although DNA methylation changes
at specific loci have been established during EMT [7,8],
changes in the global DNA methylation landscape are not
well understood. Indeed, a recent report demonstratedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Malouf et al. Genome Biology 2013, 14:R144 Page 2 of 17
http://genomebiology.com/2013/14/12/R144that DNA methylation is largely unchanged during EMT
mediated by transforming growth factor beta (TGF-β) [9],
while another showed that EMT is associated with specific
alterations of gene-related CpG-rich regions [10]. More-
over, another report showed a striking difference in DNA
methylation in non-small cell lung cancers between
mesenchymal-like tumors and epithelial-like tumors, which
display a better prognosis and exhibit greater sensitivity to
inhibitors of epidermal growth factor receptor [11].
In addition to DNA methylation, EMT mediates epigen-
etic reprogramming through widespread changes in post-
translational modifications of histones [12]. However, it is
unknown if switches in histone marks coordinate EMT
and, in particular, whether genome regulation by Polycomb
group (PcG) and Trithorax group (TrxG) proteins are crit-
ical regulators for this transition, as is the case for germ cell
development and stem cell differentiation. Indeed, the
TrxG complex activates gene transcription by inducing
trimethylation of lysine 4 of histone H3 (H3K4me3) at
specific sites, whereas the PcG complex represses gene
transcription by trimethylation of lysine 27 on histone H3
(H3K27me3). Of note, a subset of promoters in embryonic
stem cells are known to have methylation at both H3K4
and H3K27 (the bivalent state), which poise them for either
activation or repression in different cell types upon differ-
entiation [13]. However, the transcriptional dynamics and
the role of those bivalent genes in differentiated cells and
during EMTare still poorly understood.
The development of genome-wide sequencing ex-
panded our understanding of the plasticity of DNA
methylation during differentiation of embryonic stem
cells, tumorigenesis and metastasis [14,15]. During the
differentiation of embryonic stem cells into fibroblasts,
the majority of DNA methylation changes occur outside
of core promoters in partially methylated domains
(PMDs), which represent large hypomethylated regions
covering approximately 40% of our genome [14]. Using
genome-wide DNA methylation analyses, these PMDs
have been shown to be hypomethylated in adipose tissue
[16], placenta [17,18], cultured breast cancer cells [19]
and neuronal cells [20], as well as in several cancer types
[15]. PMDs overlap with domains of H3K27me3 and/or
H3K9me3, transcriptional-repression associated histone
marks, in IMR90 fibroblasts [14]. In breast cancer, wide-
spread DNA hypomethylation occurs primarily at PMDs
in normal breast cells [21]. However, whether DNA
methylome changes during EMT recapitulate tumor for-
mation remains unknown.
EMT is often a transient process, with changes in gene
expression, increased invasiveness, and acquisition of
stem cell properties such as increased tumor initiation,
metastasis and chemotherapeutic-resistance. It’s transi-
ent nature suggests that significant features of an EMT
could be regulated by epigenetic fluidity triggered by keytranscription factors and signaling events in response to an
alteration in the tumor microenvironment. We present
genome-wide changes in DNA methylation and histone
modifications in H3K4me3 and H3K27me3 following the
induction of EMT by the ectopic expression of the
transcription factor Twist1 using immortalized human
mammary epithelial cells (HMLE) [2]. Additionally, we
compared the Twist1-expressing HMLE cells, hereafter
HMLE Twist, cultured in a monolayer to the same cells
cultured as mammospheres (MS), which enriches for cells
with stem cell properties [22]. We found that EMT is char-
acterized by major epigenetic reprogramming required for
phenotypic plasticity, with predominant alterations to poly-
comb targets. Moreover, we have shown that inhibition of
the H3K27 methyltransferases EZH2 and EZH1 - part of
the polycomb repressive complex 2 (PRC2) - either by short
hairpin RNA (shRNA) or pharmacologically, blocks EMT
and stemness properties.
Results
Aberrant promoter DNA methylation induced by
epithelial-mesenchymal transition is cell-type specific
and regionally coordinated
According to the EMT model of cancer progression, epi-
thelial cells undergo a phenotypic change during the se-
quential progression of primary tumors towards metastasis,
accompanied or not by DNA methylation changes [9,10].
Although aberrant promoter methylation on some specific
promoters was previously reported [23], genomic distribu-
tion and genome-wide mapping of methylome changes
during this process remains unclear. To identify DNA
methylation changes in EMT, we used digital restriction en-
zyme analysis of methylation (DREAM), which yields highly
quantitative genome-wide DNA methylation information
[24]. Because small changes in DNA methylation could be
important, we focused the analysis on sites with a threshold
of 100-fold coverage per sample (average = 1,178 tags per
CpG site). By examining approximately 30,000 CpG sites
spanning the promoters of around 5,000 genes (Table S1 in
Additional file 1), we observed the expected relationships:
lower DNA methylation at CpG islands (CGI) compared to
non-CGI; lowest methylation around the transcription start
site (TSS) (Figure S1A in Additional file 2); and a strong
negative-correlation between promoter DNA methylation
and gene expression (Spearman’s R < −0.50, P <0.0001), in-
dependent of Twist1 expression. Interestingly, the quantita-
tive nature of the data allowed us to establish that genes
with completely unmethylated promoters (methylation
≤1%) were highly expressed in comparison to promoters
with an appreciable level of methylation (>1%; Figure 1A).
As there is an important overlap between PMD regions in
different tissues [20,25], we analyzed gene expression ac-
cording to the localization of genes in PMDs. As expected,
genes located within PMDs had lower baseline expression
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Figure 1 DNA Methylation changes occurring following epithelial-mesenchymal transition. (A) Box-plot for gene expression levels according
to promoter DNA methylation level of genes located in partially methylated domains (PMDs) (red) and outside PMDs (blue) in human mammary
epithelial cells (HMLE). The x-axis represents promoter % methylation and y-axis represents normalized expression level. *** P <0.0001, ** P <0.001, ns:
non-significant. (B) Correlation of DNA methylation level of CpG sites in HMLE vector cells (Pw) (x-axis) and HMLE Twist cells (y-axis), showing dramatic
changes in DNA methylation following EMT. (C) Correlation of DNA methylation level of CpG sites in HMLE vector cells transduced with two different
‘control’ vectors Pw (x-axis) and GFP (y-axis) showing no change in DNA methylation. (D) Box plots of average gene expression levels of genes with a
gain, loss or no change in DNA methylation. Note that a gain of DNA methylation (increase to ≥2% DNA methylation from gene promoters which
were fully unmethylated, ≤1%) was associated with 3.8-fold decrease of their expression levels, while demethylation of gene promoters leading to fully
unmethylated promoters (≤1%) was associated with an increase in their gene expression levels by about 2-fold. (E) GSEA showing that genes losing
gene body methylation following EMT are enriched for genes which are down-regulated in a CDH1-knockdown model of EMT (P <0.0001). The bottom
graph represents the rank-ordered, non-redundant list of genes. Genes on the far right (blue) correlated most strongly with decreased gene expression
in the CDH1-knockdown model of EMT. FDR, false discovery rate. (F) Box plots showing decreased expression levels of genes losing gene body
methylation following Twist-induced EMT in two different models: knockdown of CDH1 and basal breast cancers compared to luminal breast cancers.
y-axis represents the log2-fold change of gene expression.
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average gene body methylation was lower for CpG sites lo-
cated within PMDs compared to those located outside
PMDs (21.5% versus 40% respectively, P <0.0001; Figure
S1B in Additional file 2). Thus, we conclude that even low
levels of DNA methylation at promoters are inhibitory for
gene expression and genes within PMDs tend towards
lower expression.
Expression of Twist1 caused a dramatic change in DNA
methylation both at CGIs and at non-CGIs (Figure 1B)
whereas no changes were seen between cells with inde-
pendent control vectors, suggesting that the methylation
changes observed are related to Twist1 expression and not
to random clonal drift (Figure 1C). To study the impact of
these changes on gene expression, we focused on com-
pletely unmethylated genes (<1%) and identified 90 genes
out of 3,008 (3%) that switched from <1% to >2% with an
average gain of 5.4% DNA methylation. As expected, this
was associated with about a four-fold decrease in the ex-
pression of these genes (P <0.0001; Figure 1D). The gain
of methylation was higher in genes located within PMDs
(12%; 37 out of 309) versus outside PMDs (2%; 53 out of
2,699; χ2 test, P <0.0001). Conversely, there were 39 genes
that become unmethylated upon Twist1 expression, con-
comitant with around a two-fold increased expression of
the respective genes (Figure 1D), such as FOXC2, a master
regulator of EMT [26-28]. In contrast with promoter
methylation, promoter hypomethylation was more fre-
quent outside PMDs (4.6%; 31 out of 670) than within
PMDs (1.8%; 8 out of 455; P <0.02). Gene ontology (GO)
analysis for genes with methylation change associated with
gene expression change showed enrichment for cell adhe-
sion genes such as DSCAM, NID1 and NID2 (P = 0.002),
consistent with the functional change of motility and mi-
gration of mesenchymal cells. Moreover, we found an en-
richment of genes (P = 5e-05) involved in calcium binding
protein coding genes (that is, FBN1, NPNT), suggesting a
functional role for orchestrated calcium-binding proteins
in EMT that may represent a novel therapeutic target for
controlling cell plasticity. Collectively, these data suggest
that induction of EMT by Twist1 results in a moderate
change in the DNA methylation of core promoters.
Twist1 promotes global demethylation outside of core
promoters
To understand the global methylation and demethyla-
tion changes that occur in response to induction of
EMT by Twist1, we focused on 4,903 CpG sites with a
threshold detection of a minimum of 100 tags that had a
baseline methylation ≥70%, as is typical of most of the
genome [14]. Among these 4,903 CpG sites, one fifth
(18.6%) lost DNA methylation following EMT (Table S2
in Additional file 1). We obtained comparable results
using thresholds of 10 tags, and three tags per CpG site,covering 7,081 and 11,117 CpG sites respectively (data not
shown). This widespread hypomethylation was mainly ob-
served in PMDs (P <0.0001; Table S2 in Additional file 1)
and was independent of the genomic CpG location in re-
peats and lamina-associated domains (Figure S2A-C in
Additional file 3). Moreover, we found decreased methyla-
tion of repetitive elements at short interspersed nuclear el-
ements, long interspersed nuclear elements and satellite
repeats (Figure S2D in Additional file 3). Concomitant
with global PMD demethylation, we also observed focal
hypermethylation specific to those promoters (Figure S1C,
D in Additional file 2), consistent with data recently re-
ported in colon cancer [25]. These data suggest that
methylome change during EMT is reminiscent of methy-
lome changes observed in cancer.
To understand the functional relevance of gene body
methylation changes following the induction of EMT by
Twist1, we performed Gene Set Enrichment Analysis
(GSEA). GSEA is a computational method that assesses
whether a defined set of genes (herein, gene bodies)
shows statistically significant difference between two
conditions (herein, between epithelial and mesenchymal
states) [29]. While there was no enrichment for any
pathway associated with gain of gene body methylation,
GSEA reveals enrichment for gene body hypomethyla-
tion for EMT targets in the CDH1-knockdown model (P
<0.0001 [30]; Figure 1E), and for MIR34B and MIR34C
targets [31] (Table S3 in Additional file 1). Concomi-
tantly, average expression level of those hypomethylated
genes was lower after knockdown of CDH1, as well as in
basal-like compared to luminal-like breast cancer sub-
types [32,33] (P <0.004; Figure 1F). Collectively, these
data suggest that following the induction of EMT by
Twist expression, Twist reprograms the genome by
demethylating gene bodies of epithelial cell-specific
genes, leading to a decrease of their expression levels.
Twist1 increases the number of promoters with H3K4me3
by more than one fifth
Overall, the number of genes marked by H3K4me3 and
also by both H3K4me3 and H3K27me3 (bivalent) was in-
creased following Twist1-induced EMT (Figure 2A,B). Spe-
cifically, we observed that more than 20% (3,253 out of
15,853) of tallied genes acquired H3K4me3 but less than
3% (424 out of 15,853) of genes lost H3K4me3 (Figure 2C).
As expected, acquisition of H3K4me3 was associated with
increased mRNA expression whereas loss of H3K4me3
led to reduced expression of the corresponding genes
(Figure 2D). GO analysis indicated that the set of genes that
lose H3K4me3 is significantly enriched for genes associated
with cell adhesion and differentiation (Figure 2E). Con-
versely, gain of H3K4me3, which is mediated by the TrxG
complex, was found in EMT-promoting transcription fac-
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Figure 2 H3K4me3 dynamic modifications are coupled with transcriptional changes related to epithelial-mesenchymal transition
genes. (A) Pie chart showing the distribution of H3K4me3 and H3K27me3 marks in human mammary epithelial cells (HMLE) vector cells and
HMLE Twist cells. (B) Landscape of H3K4me3 for CDH1 (loss of H3K4me3 in vector cells) and ZNF75A (gain of H3K4me3) in HMLE Twist cells. (C)
Venn diagram of H3K4me3 at gene promoters in HMLE vector cells and HMLE Twist cells. (D) Box plots for gene expression changes in genes
losing or gaining the H3K4me3 mark. (E) Gene ontology analysis using DAVID for genes losing the H3K4me3 mark. The x-axis represents the
P-value levels and y-axis the gene ontology pathways. (F) Gene ontology analysis using DAVID for genes gaining the H3K4me3 mark. The x-axis
represents the P-value levels and y-axis the gene ontology pathways.
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matin remodeling during EMT (Figure 2F). GSEA sho-
wed enrichment for estrogen receptor (ESR1) targets
(P <0.0001, false discovery rate (FDR) q <0.05) within genes
losing H3K4me3 (Table S4 in Additional file 1). As a result,
ESR1 targets in HMLE vector cells lose the active mark
H3K4me3 consistent with the three-fold decrease of ESR1
expression in HMLE Twist cells (data not shown). Import-
antly, genes losing H3K4me3 were also enriched for genes
down-regulated in blood vessel cells from the wound site,
suggesting epigenetic conservation of the EMT process be-
tween wound healing and cancer (Table S4 in Additional
file 1). Thus, EMT is accompanied by a widespread gain in
H3K4me3-mediated gene activation, and loss of H3K4me3
at ESR1 targets.Switches between H3K4me3 and H3K27me3 modulate
transcriptional dynamics
Using chromatin immunoprecipitation sequencing
(ChIP-seq) for the H3K27me3 repressive histone modifi-
cation, we found that the genomic distribution of
H3K27me3 was significantly reduced in HMLE Twist
cells (250 Megabases in vector cells compared to 153
and 138 Megabases in HMLE Twist cells cultured in
monolayer and spheres, respectively; data not shown).
This is consistent with the notion that cells that have
undergone EMT are less differentiated and have ac-
quired stem cell properties [6]. Given these changes in
the landscape of H3K27me3, we investigated switches
between H3K27me3 and H3K4me3 during EMT. Ex-
pression of Twist1 caused a loss of H3K27me3 in more
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cells (Figure 3A,B). Of the 2,070 genes that lost H3K27me3,
approximately 11% (225 out of 2,070) switched to
H3K4me3 (Figure 3C) and we found that transcription of
these genes was dramatically induced (around five-fold;
P <0.0001). Conversely, the genes that lost H3K27me3
without gain of H3K4me3 had no average change in their
respective gene expression (Figure 3C). Overall, 102 genes
switched from H3K4me3 to H3K27me3 after Twist1-
induced EMT, and were transcriptionally repressed by more
than 32 fold (Figure 3C). These chromatin switches were
associated with differential gene expression, particularly at
typical EMT markers. For example, the repression of E-
cadherin expression during EMT correlated with a switch
from H3K4me3 to H3K27me3 (Figure 3B). Conversely,
gain of N-cadherin expression correlated with a switch
from H3K27me3 to H3K4me3. Strikingly, the same inter-
play between H3K4me3 and H3K27me3 occurs for master
genes involved in the EMT process, such as PDGFRα,
which is essential for Twist1 to promote tumor metastasisA
C
B
Figure 3 H3K27me3 switches orchestrate a mesenchymal cell-type sp
marked by H3K27me3 in human mammary epithelial cells (HMLE) vector c
gene (gain of H3K27me3 mark in HMLE Twist cells). (C) Box-plot of gene e
switching in HMLE vector cells from H3K4me3, H3K27me3, bivalent or neithvia invadopodia [34], and the splicing regulator ESRP1,
which is repressed by Snail1 to promote EMT [35] (Table
S5 in Additional file 1). Among genes with highly altered
expression during EMT increasing or decreasing at least
nine fold), 23.1% of them switched between H3K4me3 and
H3K27me3 marks, as compared to only 2.8% for genes
without highly altered expression (Figure S3 in Additional
file 4). Altogether, these data suggest that an epigenetic pro-
gram orchestrated by TrxG or PcG complexes regulate key
EMTgenes.
During EMT, parallel to the dramatic loss of H3K27me3
occupancy in nearly 50% of genes (n = 2,070) marked in
HMLE vector cells, mesenchymal cells gained H3K27me3
at 1717 genes. GSEA analysis showed that these genes
were enriched for functional categories in a cell-type spe-
cific manner. Indeed, the set of genes which gained
H3K27me3 is related to genes down-regulated in a previ-
ously described CDH1 knockdown model of EMT [30]
(Figure 4A) and to genes with low expression in basal-like
as compared to luminal-like breast cancer cell lines [32]ecific gene expression signature. (A) Venn diagram of genes
ells and HMLE Twist cells. (B) Landscape of H3K27me3 mark in CDH1
xpression (the bars represent 10% and 90% extremes) for genes


















Figure 4 Gene set enrichment analysis of H3K27me3 marks. (A) Gene set enrichment analysis showing positive enrichment for H3K27me3
marks in genes which are down-regulated by the CDH1-knockdown model of EMT (P <0.0001). The bottom graph represents the rank-ordered,
non-redundant list of genes. Genes on the far left (red) correlated the most with decreased gene expression following CDH1-knockdown. The vertical
black lines show the position of each of the genes of the studied gene set in the ordered, non-redundant data set. The green curve is related to the
enrichment score curve. (B) Gene set enrichment analysis showing positive enrichment for H3K27me3 marks in genes distinguishing luminal from basal
like breast cancer (P <0.0001). (C) Pie chart showing that the majority of downregulated genes in the CDH1-knockdown model of EMT which gain
H3K27me3 in Twist1-cells were also pre-marked by H3K4me3 in vector cells. FDR, false discovery rate; NES, normalized enrichment score.
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interest, the majority of genes down-regulated by CDH1
knockdown and which gained H3K27me3 in Twist1-
induced cells were pre-marked by H3K4me3 in HMLE cells,
highlighting the importance of TrxG and PcG switches in
defining cell identity during EMT (Figure 4C). Furthermore,
GSEA revealed that genes belonging to pathways that gained
H3K27me3 were associated with DNA repair and mRNA
splicing (Table S6 in Additional file 1). Conversely, genes be-
longing to pathways that lost H3K27me3 were associated
with mitotic pre-metaphase and undifferentiated cancer sig-
nature (Table S6 in Additional file 1).
Importantly, we sought to investigate if the changes we
observed in Twist cells could be replicated in other EMT
model systems such as Snail and TGF-β1-induced model
systems. If we found similar findings across multiple EMT
models, this would rule out adaptation and suggest that
the effect we observed in Twist cells was due to EMT and
not necessarily adaptation. In fact, we found that the ma-
jority of sites (14 out of 17) demonstrated the same di-
rectional change in H3K4me3 and/or H3K27me3 by
ChIP-qPCR in HMLE Snail, TGF-β1 and Twist cells as we
observed by ChIP-seq in HMLE Twist cells (Figure S4 in
Additional file 5). The Pearson correlation coefficients for
Snail versus Twist (r = 0.8982, P <0.0001), for Snail versus
TGF-β1 (r = 0.4613, P = 0.006) and for TGF-β1 versus
Twist (r = 0.1791, P = 0.3108) point to close similarities be-
tween Snail- and Twist-induced EMTs in their effects on
H3K4me3 and H3K27me3 whereas expression of TGF-β1
has a less similar effect (Figure S5 in Additional file 6). We
also observed similar results for the methylation of DNA
elements assessed using bisulfite sequencing in the pro-
moters of seven genes randomly chosen out of genes
switching between H3K27me3 and H3K4me3 (Figure S6
in Additional file 7, Figure S7 in Additional file 8 and
Figure S8 in Additional file 9). Collectively, our data sug-
gest that our a majority of changes due to Twist expres-
sion are not due to adaptation but rather shared with cells
undergoing EMT through other means.
Enrichment in bivalent genes upon Twist1 induction
Bivalent genes were characterized initially in stem cells
by the co-occurrence of H3K27me3 (repression) and
H3K4me3 (activation) at genes which become either tran-
scriptionally active (H3K4me3) or repressed (H3K27me3)
upon differentiation [13]. We found that the number of
bivalent genes increased by more than 2.7-fold in HMLE
Twist cells (n = 1,248; Figure 5A), as was the case for
HOX genes (for example, HOX11; Figure 5B). The num-
ber of bivalent genes was further enriched by almost four
fold in stem cell-enriched MS culture (n = 1,628) as com-
pared to baseline of 464 genes in HMLE vector cells
(Figure 5C). These data are consistent with the notion that
the mesenchymal cells generated via EMT are lessdifferentiated and that this feature is further enriched in
MS culture. Overall, of all genes marked by H3K27me3,
34.1% were bivalent (1,249 out of 3,659) in HMLE Twist
cells compared to 11.6% in HMLE cells (464 out of 4,012).
The majority of bivalent genes in HMLE Twist cells were
pre-marked by H3K4me3 or H3K27me3 in HMLE cells
(Figure 5D). Thus, Twist-induced chromatin changes indi-
cate a reverse differentiation state, with more ‘poised’
genes and, therefore, greater plasticity. Using GO analysis,
we found that the newly bivalent genes in Twist1 cells
were enriched for genes involved in neuron differentiation,
cell morphogenesis, axonogenesis and cell fate commit-
ment both in monolayer and sphere cultures (Figure 5E,
F). This is consistent with the notion that genes involved
in differentiation acquire a poised state in less differenti-
ated cells. Of note, more than 50% (825 out of 1,628) of
bivalent genes found in MSs were also bivalent in embry-
onic stem cells.
Chromatin changes in spheroid cultures
Cells with stem cells properties are known to initiate
sphere formation in non-attachment cultures including
the cells induced to undergo EMT. Whereas previous
work has shown that sphere culture actually decreases
the number of bivalent genes [36], we observed an in-
crease in the number of bivalent genes from 464 to
1,628 (Figure 5C). Furthermore, we compared the ex-
pression of genes, DNA methylation and histone modifi-
cations of HMLE Twist cells cultured in monolayers
(two dimensional) or in MS (three dimensional) and
found that the DNA methylation in the two states was
highly similar (Spearman’s R >0.96, P <0.0001; Figure
S9A in Additional file 10). By contrast, we found that
2.6% of the genes (849 out of 33,004) increased their ex-
pression more than four fold and 2.2% (737 out of
33,004) decreased their expression more than four fold
when transitioned from monolayer to MS culture. GSEA
analysis revealed positive enrichment for different path-
ways related to interferon responses (Table S7 in Additional
file 1); by contrast, there was negative enrichment (exclu-
sion) for pathways involved in proliferation [37], as well as
for genes up-regulated in grade 3 versus grade 1 invasive
breast cancer tumors [38] (Table S7 in Additional file 1).
Consistent with earlier findings in an ovarian cancer model
[36], there was a significant switch toward more genes
marked by H3K27me3 in MS cells (3,607) compared to
monolayer (2,411; Figure S9B in Additional file 10), but the
majority of these genes were already transcriptionally si-
lenced in monolayer culture in response to the overexpres-
sion of Twist1. This was also the case for the 186 genes
switching from H3K4me3 in monolayer to H3K27me3 in
MS. Remarkably, there was a loss of H3K4me3 mark in
2,894 genes when cultured in MS compared to monolayer
(Figure S9B in Additional file 10). We then asked whether
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Figure 5 Bivalent genes are highly enriched in mesenchymal cells. (A) Venn diagram of bivalent genes in human mammary epithelial
(HMLE) vector cells and HMLE Twist- cells. (B) Landscape of H3K4me3 and H3K27me3 mark for the homeobox gene HOXA11. Note that HOXA11
is marked by H3K27me3 in both epithelial and mesenchymal cells. In HMLE Twist cells, HOXA11 gains H3K4me3 mark in addition to H3K27me3
mark. (C) Bar graph showing the number of bivalent genes in HMLE vector cells, and HMLE Twist cells in a monolayer (Twist-2D) and sphere
culture (Twist-MS). (D) Changes in histone modifications among genes becoming bivalent in HMLE Twist cells (Twist-2D) as compared to HMLE
vector cells. (E) Gene ontology of newly bivalent genes in HMLE Twist cells cultured in monolayer (Twist-2D). (F) Gene ontology of newly bivalent
genes in HMLE Twist cells cultured in spheres (Twist-MS). 2D, monolayer; MS, mammosphere.
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cells cultured in spheres were consistent with gene expres-
sion changes despite culture condition, and found that this
was the case (Figure S9C in Additional file 10). These data
suggest that changes in H3K4me3 and H3K27me3 distribu-
tion accompany a Twist1-driven EMT, either cultured in
monolayer or spheres.
Chromatin interplay between DNA methylation and
histone modifications
Because our data suggest that both DNA methylation
and histone modifications are altered throughout the
genome following Twist1-induced EMT, we examined
the relationship between these different modifications.
We found that low-level gain of DNA methylation in
promoter regions was associated with a significant in-
crease in H3K27me3 in both Twist1 monolayer and MSculture (Figure 6A). This was validated by bisulfite sequen-
cing in seven selected gene promoters switching from
H3K4me3 in HMLE vector cells to H3K27me3 in HMLE
Twist cells (Table S8 in Additional file 1). Conversely, loss
of DNA methylation was not associated with loss or gain
of H3K27me3 (Figure 6B). Furthermore, both in HMLE
and HMLE Twist cells, we found a strong positive correl-
ation between low-level DNA methylation at the promoter
and the presence of H3K27me3 (Spearman’s R >0.34,
P <0.0001). Interestingly, the association between gene si-
lencing and enrichment of H3K27me3 around TSSs was
much more pronounced in genes located in PMDs
(Figure 6C) than outside PMDs (Figure 6D).
To assess whether there is an opposing correlation be-
tween H3K4me3 and DNA methylation, we focused on
the gene promoters that gain DNA methylation and de-
crease gene expression by two fold or more. Overall, 22


















































Figure 6 Correlation between DNA methylation and H3K27me3 mark. (A) During epithelial-mesenchymal transition (EMT), gain of DNA
methylation (≥2%) at selected promoters in human mammary epithelial (HMLE) Twist cells cultured either in monolayer (green) or spheres (red)
and which were completely unmethylated (≤1%) in HMLE vector cells (blue) is accompanied by gain of the H3K27me3 mark. The x-axis repre-
sents distance from the CpG sites gaining DNA methylation to the transcription start sites (TSS). The y-axis represents average intensity of
H3K27me3 peaks. (B) During EMT, loss of DNA methylation (≤2%) of selected promoters in HMLE Twist cells cultured either in monolayer (green)
or spheres (red) and which were methylated in HMLE vector cells (blue) is not associated with change of H3K27me3 distribution. The x-axis
represents distance from the CpG sites losing DNA methylation to the TSSs. The y-axis represents average intensity of H3K27me3 peaks. (C)
Distribution of H3K27me3 marks in partially methylated domain (PMDs) in HMLE Twist cells cultured in a monolayer (green) and spheres (red) as
compared to HMLE vector cells. (D) Distribution of H3K27me3 marks outside PMDs in HMLE Twist cells either cultured in a monolayer (green) or
as spheres (red) as compared to HMLE vector cells.
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firming the opposing relationship between DNA methy-
lation and H3K4me3 (data not shown). Conversely, out
of the 19 gene promoters losing DNA methylation and
gaining expression, six genes gained a de novo H3K4me3
mark, while the 13 other genes that already had a
H3K4me3 mark in HMLE vector cells kept it in HMLE
Twist cells.
Epigenetic plasticity mediated by EZH2 is required for
epithelial-mesenchymal transition
We then asked if there is any chromatin regulator that
may explain gene expression changes during EMT. In-
genuity Pathway Analysis was used to investigate chro-
matin regulators capable of altering major changes in
gene expression during EMT. We identified EZH2 as
one of the top upstream regulators to be inhibited fol-
lowing EMT (P = 8.25e-11; Figure 7A; Table S9 inAdditional file 1). In our HMLE model, following EMT,
we did not observe an alteration in expression of EZH2,
which could account for a change in PRC2 activity. Never-
theless, our ChIP-seq revealed a decrease in H3K27me3
peak lengths, presumably mediated by EZH2 by more than
half. Furthermore, out of 37 EZH2 target genes identified
by IPA as repressed, approximately one third (n = 11) were
repressed through gain of H3K27me3; for the remaining
26 genes, this was independent of PRC2 activity. Thus, we
reasoned that post-translational modification of EZH2
may account for a decrease in methyltransferase activity
and consequent repression of its target genes. In fact,
phosphorylation of EZH2 at serine residue 21 is known to
significantly affect its function [39,40]. Thus, we used im-
munofluorescence to examine gain of phosphorylation in
EZH2 at serine residue 21 in HMLE Twist cells relative to
control cells. We observed a striking increase in phos-
phorylation of EZH2 in HMLE Twist cells (Figure 7B).
Figure 7 Phosphorylation of serine residue 21 of EZH2 is increased following epithelial-mesenchymal transition. (A) Ingenuity Pathway
Analysis showing inhibition of EZH2 as a potential upstream regulatory event following Twist-induced epithelial-mesenchymal transition. Overall,
37 target genes were predicted to be inhibited by EZH2. (B) Immunofluorescence showing increase of phosphorylation of EZH2 at serine residue
21 in human mammary epithelial (HMLE) Twist cells as compared to HMLE vector cells.
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account for decreased trimethylation of H3K27 notwith-
standing inhibition of EZH2 target genes through a PRC2-
independent mechanism.
We then asked whether EZH2 is also required for the
EMT. We examined the importance of EZH2 in Twist-
induced EMT. While the expression of EZH2 was not sig-
nificantly altered following the expression of Twist1 or
other EMT-inducing factors in HMLE cells (Figure 8A),
the suppression of EZH2 using shRNA was sufficient to
reduce the level of H3K27me3 (Figure 8B,C). In addition,
reduction of EZH2 significantly reduced the number of
MSs compared to the control shRNA expressing cells
(Figure 8D). This reduction in sphere formation was not
due to changes in cell growth rates in monolayer culture
(Figure 8E) or changes in the expression of EMT-
promoting transcription factors (Figure S10 in Additional
file 11). Interestingly, knockdown of the EZH2 homolog
EZH1 (also a part of the PRC2 complex) mimics the
sphere-formation defect similarly to EZH2 knockdown
(Additional file 12: Figure S11). Furthermore, reduction of
EZH2 protein using 3-deazaneplanocin A [41] wassufficient to reduce both H3K27me3 and sphere formation
(Figure 8F,G). Notably, the sphere assay was performed in
the absence of the drug, following an 8-day pretreatment
and a 48-hour interim period to avoid cytotoxicity during
sphere growth. Furthermore, the morphology of HMLE
Twist cells following 3-deazaneplanocin A treatment was
more epithelial than control-treated cells (Figure 8H). To-
gether, these results indicate that EZH2 plays an essential
role in the pathophysiology of EMT through PRC2-
dependent and -independent mechanisms.
Discussion
The findings presented here provide the first compre-
hensive genome-wide demonstration of the remodeling
of the epigenome following Twist1-induced EMT, in
terms of DNA methylation as well as trithorax and
polycomb-related histone modifications, concurrent with
quantitative gene expression analysis by RNA-seq. In
particular, we show evidence that genome-wide DNA
methylation changes involve focal hypermethylation and
global hypomethylation of PMDs, reminiscent of methy-
lome changes observed between normal mammary cells
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Figure 8 EZH2 is required for Twist-induced stemness. (A) Quantitative reverse transcription polymerase chain reaction expression of EZH2 in
human mammary epithelial (HMLE) cells expressing the indicated epithelial-mesenchymal transition (EMT) inducers. (B) EZH2 protein levels
assessed by western blot in HMLE Twist cells transduced by vectors expressing two different short hairpin RNAs (shRNAs) targeting EZH2 and a
control vector (FF3). Note that ShRNA #2 was more efficient in reducing EZH2 protein levels as indicated by western blot. (C) Histone H3 and
H3K27me3 protein levels assessed by western blot indicate that shRNA #2 reduces H3K27me3. (D) Mammospheres were counted in HMLE Twist
FF3 cells (control) and shEZH2 cells grown in mammosphere-promoting conditions. Spheres greater in size than 50 micrometers after 10 days
were counted and a Student’s t-test was performed. (E) Count of HMLE Twist FF3 (control) and shEZH2 cells after multiple days in standard cell
culture conditions. (F) Western blot analysis of H3K27me3 level in HMLE Twist cells before and after treatment with 3-deazaneplanocin A. (G)
HMLE Twist cells were treated with 2.5 μM of 3-deazaneplanocin A for 8 days followed by 48 hours without drug. Surviving cells were then
subjected to a sphere assay in the absence of drug for 8 days. (H) The morphology of HMLE Twist cells treated with 2.5 μM 3-deazaneplanocin
A is depicted after 8 days of treatment. We observed a change toward an epithelial morphology.
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that EMT recapitulates DNA methylation changes ob-
served during breast cancer carcinogenesis [21]. As with
embryonic stem cell differentiation, the majority of
changes occur outside core promoters, suggesting that
cell plasticity, even in differentiated cells, involves a pro-
found change in the DNA methylome and histone pack-
aging. These data are in contrast with data reported
recently showing unchanged DNA methylation during
EMT mediated by TGF-β [9]. One explanation could be
that the 36-hour exposure to TGF-β was too short to
observe changes in DNA methylation. In addition, our
analysis of H3K4me3 and H3K27me3 ChIP data from
HMLE Snail, Twist and TGF-β cells indicates that TGF-
β cells are more divergent than EMT induced by Snail
and Twist, an observation that was initially made using
microarray data in Taube et al. [33]. Nevertheless, our
data provide powerful evidence to support the viewpoint
recently brought forward by Pujadas and Feinberg that
shifts in distinct regions of the epigenetic landscape, in
our case PMDs, undergird cellular plasticity in both de-
velopmental and disease contexts [42].
Unexpectedly, our DREAM analysis found that a small
gain of promoter DNA methylation is often coupled
with a gain of H3K27me3, which strongly suggests thatDNA methylation and PcG proteins act together. Indeed,
DNA methylation is linked to polycomb protein-
mediated repression; however, there is a debate as
to whether DNA methylation and PcG proteins act
together [43] or independently [44,45] to silence gene
expression. Deep sequencing allows more accurate mea-
surement in the low methylation range and the etiology
and functional significance of small changes in DNA
methylation is unknown. Although DNA methylation
could be contributing to gene silencing, it is also pos-
sible that silencing by PcG proteins weakens protection
against DNA methylation and thus indirectly promotes
small increases. It is interesting that remodeling at
PMDs was associated with both DNA hypermethylation
of promoters and global demethylation; we speculate
that a redistribution of TET (ten-eleven-translocation)
and DNMT (DNA (Cytosine-5-)-Methyltransferase) pro-
teins may facilitate plasticity during EMT [46].
Most strikingly, cells that had undergone EMT dis-
played a large increase in the number of bivalent genes.
Certainly, these poised genes might help mediate the
stem cell properties previously reported in this model.
How Twist1 leads to this gain of bivalency deserves fur-
ther investigation; however, this is the first description
of remodeling involving differentiated cells having
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cells [13].
Beyond the pure description of the landscape of DNA
methylation and histone changes, these data provide a
holistic framework for studying EMT-mediated changes
in chromatin and gene expression. Indeed, our data
show that key EMT markers switch between H3K4me3
and H3K27me3. As an example, we found an opposing
histone switch for E-cadherin and N-cadherin, and that
the expression change was associated with histones
switches but not with DNA methylation changes. In fact,
E-cadherin lost H3K4me3 and gained H3K27me3,
whereas N-cadherin did the opposite. Moreover, other
EMT regulators (different from EMT markers) were also
found to be subject to H3K4me3 and H3K27me3
switches, such as ESRP1 and PDGFα, which are known
to be involved in splicing and invadopodia formation re-
spectively [34,47]. Therefore, we speculate that other
genes that exhibit histone modification switches are key
EMT genes and deserve more focus in the study of this
process. Indeed, with the development of deep sequen-
cing and the decreased cost of sequencing, we speculate
that alterations in histone landscape may be used in the
future as a tool for drug discovery.
Lastly, we have shown that both the epigenetic modifiers
EZH2 and EZH1 are essential for the stemness property of
cells that have undergone EMT in response to Twist1 ex-
pression. EZH2 is a known marker of aggressive breast can-
cer [48], specifically through an influence on cancer stem
cells [49], but a link to EMT has not yet been described.
Because the expression of either EZH2 or EZH1 was not
significantly altered by EMT, we hypothesize that the EMT-
induced changes in the H3K27me3 landscape are mediated
primarily by changes in EZH2 or EZH1 localization and
function. Of note, the suppression of EZH2 by shRNA and
pharmacologically by 3-deazaneplanocin A was sufficient
to reduce both H3K27me3 and sphere formation, opening
avenues for the use of EZH2 inhibitors to reverse EMT-
induced tumor resistance to hypoxia or chemotherapeutics.
Further work is called for to detail the mechanisms leading
to these changes. Currently, there are active efforts to de-
velop EZH2 inhibitors for cancer therapy, and our data
suggest that they may also be useful to suppress epigenetic
plasticity and its physiological consequences, such as me-
tastasis and drug resistance.
Conclusions
We show that induction of EMT results in dramatic al-
terations in the epigenetic landscape involving significant
changes in both DNA methylation (mainly outside core
promoters) and histone modifications (that is, an in-
crease in bivalent genes, gene switching between
H3K4me3 and H3K27me3) and that these changes con-
tribute to the stem cell properties and increase cellularplasticity. Thus, inhibiting epigenetic remodeling may
block plasticity which facilitates EMT and associated
breast cancer metastasis.
Methods
Characterization of human mammary epithelial cells
HMLE Twist cells were derived as shown in Yang et al.
[2]. Briefly, we overexpressed Twist1 using retroviral
vectors and the transduced cells were selected using
puromycin. This method yields a very high transduction
rate (>99%). To further confirm the homogeneity of this
population of cells, we performed immunofluorescence
for VIM and FOXC2 markers, which are known to be in-
duced following EMT (Figure S12 in Additional file 13).
Similar results were obtained for HMLE Snail and
HMLE TGF-β1 cells ( Figure S13 in Additional file 14).
Digital restriction enzyme analysis of methylation methods
DREAM was performed as reported previously [50].
Briefly, genomic DNA was sequentially digested with a
pair of enzymes recognizing the same restriction site
(CCCGGG) containing a CpG dinucleotide, as previously
reported. The first enzyme, SmaI, cut only at unmethy-
lated CpG and left blunt ends. The second enzyme, XmaI,
was not blocked by methylation and left a short 5′ over-
hang. The enzymes thus created methylation-specific sig-
natures at the ends of digested DNA fragments. These
were deciphered by next-generation sequencing using
the Illumina Gene Analyzer II and Hiseq2000 platforms
(Illumina, San Diego, CA, USA). Methylation levels for
each sequenced restriction site were calculated based on
the number of DNA molecules with the methylated or
unmethylated signatures. Overall, we acquired around 36
million sequence tags per sample that were mapped to
unique CpG sites in the human genome, using version
hg18. Details of the DREAM method were previously re-
ported by Challen et al. [50].
Genome annotation of DREAM data and statistical analysis
Genomic regions were defined according to National
Center for Biotechnology Information coordinates
downloaded from the University of California Santa
Cruz website [51] in April 2010. Promoters were defined
as regions between −1,000 bp and +1000 bp from TSSs
for each RefSeq transcript. Gene bodies were defined as
the transcribed regions, +1,000 bp from TSS to the end
of the transcription sites for each RefSeq transcript. To
calculate promoter methylation, we averaged the methy-
lation level of all CpG sites located between −1000 bp
and 1000 bp of the TSS. To estimate the FDR of pro-
moter methylation using our method, we reasoned that
a comparison of HMLE cells transduced with Twist1 ac-
cording to culture conditions (monolayer versus MS)
could be used because their methylation was remarkably
Malouf et al. Genome Biology 2013, 14:R144 Page 14 of 17
http://genomebiology.com/2013/14/12/R144identical (Spearman’s R >0.96, P <0.0001; Figure S3B in
Additional file 4). The FDR was 0% for 5% gain of methy-
lation for unmethylated genes (≤1%), and 0.001 (5 out of
4,655) for a difference of 2% of methylation for unmethy-
lated genes (≤1%). Of note, a different transduction of
HMLE with a different vector led to a minimal change of
promoter methylation with 20 genes out of 3,933 genes
gaining 2% methylation at unmethylated loci (≤1%). Using
a minimum of 300 tags per SmaI site, only 7 out of 3,933
unmethylated genes gained more than 2% methylation,
confirming the method’s high level of precision.
Because the majority of the genome is heavily methyl-
ated in contrast to CpG sites related to promoters located
in CGI, we used different criteria to analysis DNA methy-
lation changes at the genome level. Arbitrarily, we consid-
ered that CpG sites with methylation level ≤10% were
unmethylated and a threshold gain of 20% was defined as
hypermethylation; conversely, CpG sites with methylation
level ≥70% were considered methylated and a threshold
loss of 20% was defined as hypomethylation.
For the localization of CpG sites in PMDs or outside
PMDs, we downloaded data published for fetal lung fibro-
blasts (IMR90) [14]. The genes were considered to be lo-
cated in PMDs if their promoters were located within
PMDs. The graphs were prepared using GraphPad Prism
5.0 for Windows, GraphPad Software, San Diego California
USA. For the graph of the distribution of CpG sites de-
tected by DREAM, we average 25 to 50 neighbor points ac-
cording to their distance to TSS, and the data were then
smoothed using GraphPad Prism 5.0.
For gene body methylation, the average of CpG sites lo-
cated +1000 bp from the start of transcription to the tran-
scription end site was calculated. For GSEA, gene sets
were downloaded from the Broad Institute’s MSigDB web-
site [29]. Gene set permutations were used to determine
statistical enrichment of the gene sets using the difference
of methylation between Twist1-transduced cells (mono-
layer) and vector cells.
Chromatin immunoprecipitation-sequence generation
and mapping
ChIP-seq experiments performed for H3K4m3 and
H3K27me3 produced more than 10 million uniquely
mapped tags per chromatin modification. ChIP was per-
formed according to the Abcam protocol [52] with few
modifications. Library preparation and sequencing were
performed on an Illumina/Solexa Genome Analyzer II
or Hiseq 2000 in accordance with the manufacturer’s
protocols. ChIP-seq reads were aligned to the human
genome (hg18) using the Illumina Analyzer pipeline.
Unique reads mapped to a single genomic location
were called peaks using the MACS software (version
1.3.7.1) for H3K4me3 marks (the window was 400 bp,
and the P-value cutoff = 1e-5) [53].For peak calling of H3K27me3, SICER (version 1.03)
was used to detect peaks and enriched domains as the
peaks were large and not as sharp as for H3K4me3 [54].
The window size was set as 200 bp as default. The gap
size was determined as recommended by Zang et al.
[54], or at most 2 kb, since the performance worsens as
the gap size increases beyond more than 10 times the
window size. Following Wang et al. [55], the E-value
was set at FDR ≤5%, which was estimated as E-value
(the expected number of significant domains under the
random background) divided by the number of identified
candidate domains. The FDR cutoff to further filter out
the candidate domains by comparing to control was set
as 5%.
Sequencing reads for histone H3 DNA were used as
control for MACS and SICER. Annotated RefSeq genes
with a peak located at their promoters (−1 kb to +0.5 kb
of TSS) were identified as being marked by H3K4me3 or
H3K27me3 modifications. For the pathway analysis, GO
analysis was done using DAVID [56,57]. DAVID analyses
were performed online using parameters of EASE value
of <1 × 10–5, count of >10, fold enrichment of >2 and
Bonfferroni of <1 × 10–2. For GSEA, gene sets were
downloaded from the Broad Institute’s MSigDB website
[29]. Gene set permutations were used to determine
statistical enrichment of the gene sets using the fold en-
richment difference in histone modifications between
H3K4me3 and H3K27me3 of mesenchymal cells (Twist1
cells) and vector cells.
To exclude the possibility of technical variations, we
performed technical (independent IP) replicates for the
ChIP of H3K4me3 and H3K27me3 in HMLE cells trans-
duced with Twist1 and cultured in spheres followed by
sequencing. Likewise, we performed a technical replicate
for ChIP of H3K27me3 in HMLE vector cells. We ob-
tained high correlations between the technical replicates
(r >0.82; Table S10 in Additional file 1), suggesting that
our findings were not due to chance. A list of primers
used for ChIP-qPCR validation of selected genes is avail-
able in Table S11 in Additional file 1.
RNA-sequence library generation and mapping
RNA extraction from vector cells and Twist1-transduced
cells (monolayer and sphere) were done with Trizol re-
agent (Invitrogen, 15596–026). Library preparation was
done using a SOLiD™ Total RNA-seq Kit accord-
ing to the manufacturer’s protocol (Life Technologies,
Carlsbad, CA, USA). Reads sequenced produced by the
SOLiD analysis pipeline were aligned with to the Na-
tional Center for Biotechnology Information BUILD
hg19 reference sequence. Short reads were mapped to
the human reference genome (hg19) and exon junctions
using the ABI Bioscope (version 1.21) pipeline with de-
fault parameters. Only the tags that mapped to the hg19
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that aligned to multiple positions were excluded. Tags
mapped to RefSeq genes were counted to derive a meas-
ure of gene expression. To compare the gene expression
values, we reasoned that cell type change associated with
EMTcould result in a change in the total amount of RNA.
We therefore used the most conservative normalization
by assuming most genes did not change their expression.
This was done by constructing a histogram of expression
ratio and by assuming that the maximum of the histogram
corresponded to no change in gene expression. When
compared to the normalization procedure where the total
tags mapped to the genes were assumed to be constant,
the differences were less than 10%.
Data availability
All sequencing data and processed files are available on
Gene Expression Omnibus accession number [GEO:
GSE53026].
Additional files
Additional file 1: Table S1. Coverage of sequencing of CpG sites using
DREAM. Table S2. Characteristics of CpG sites in HMLE vector cells that
lose and gain DNA methylation in HMLE cells transduced with Twist1.
The minimal number of tags used by CpG site is ≥100 tags. Table S3.
GSEA of top 10 pathways that have differentially gene body methylation
in HMLE Twist cells as compared to HMLE vector cells. Table S4. Top
GSEA for genes marked by H3K4me3 that display statistically significant
fold change enrichment in HMLE Twist cells as compared to HMLE vector
cells. Table S5. Genes presenting promoter switches for H3K4me3 to
H3K27me3 histone marks between HMLE vector and HMLE Twist cells.
Table S6. Top GSEA for genes marked by H3K27me3 that display
statistically significant fold change enrichment in HMLE Twist cells as
compared to HMLE vector cells. Table S7. Top GSEA for differentially
expressed genes between HMLE Twist cells as compared to HMLE vector
cells. Table S8. Summary of relationship between DNA methylation and
histone modifications for selected genes. Table S9. Top upstream
regulators identified using Ingenuity Pathway Analysis for differentially
expressed genes between HMLE Twist cells as compared to HMLE vector
cells. Table S10. Summary of technical ChIP-seq replicates performed.
Table S11. List of ChIP-qPCR primers used in the study of H3K4me3 and
H3K27me3.
Additional file 2: Figure S1. Description of DREAM data. (A) DNA
methylation level (y-axis) of CpG sites located in CGI (green) and non-CGI
(red) according to the distance to the TSS (x-axis). Note the higher level
of gene body methylation in comparison to the methylation levels of
upstream regions. (B) DNA methylation level (y-axis) of CpG sites located
in PMDs (red) and outside PMDs (green) according to the distance to TSS
(x-axis). (C) Average DNA methylation levels (y-axis) of CpG sites located
in PMDs of HMLE vector cells (blue) and HMLE Twist cells (red). x-axis
represents distance of CpG sites to TSS. Note global DNA demethylation
of PMDs in mesenchymal cells coupled with increased methylation at
promoters. (D) Average DNA methylation levels (y-axis) of CpG sites
located outside PMDs in HMLE vector cells (blue) and HMLE Twist cells
(red). x-axis represents distance of CpG sites to TSS. Note the absence of
global DNA demethylation as it is the case for DNA methylation within
PMDs.
Additional file 3: Figure S2. Average DNA methylation levels in
different genomic locations. (A) Average DNA methylation level of CpG
sites located within/outside partially methylated domains (PMDs) and/or
repetitive elements. ns stands for not significant. * P <0.05. (B) Average
DNA methylation level of CpG sites located within/outside PMDs and/orCpG islands. (C) Average DNA methylation level of CpG sites located
within/outside PMDs and/or lamina associated domains. (D) Average
DNA methylation level of CpG sites located in repetitive elements of
HMLE vector cells (blue) and in HMLE Twist cells cultured in monolayer.
***P <0.0001.
Additional file 4: Figure S3. Histone switches of highly up-regulated
and down-regulated genes in HMLE Twist cells as compared to HMLE
vector cells. The majority of genes that become up-regulated in
mesenchymal cells and were pre-marked by H3K27me3 in vector cells
switched to H3K4me3 in HMLE Twist cells. Conversely, the majority of
genes that become down-regulated in mesenchymal cells and were
pre-marked by H3K4me3 in vector cells switched to H3K27me3.
Additional file 5: Figure S4. ChIP-qPCR results for H3K4me3 and
H3K27me3 in 17 loci in HMLE vector cells, and HMLE Twist-, Snail- and
TGF-β1-mediated EMT.
Additional file 6: Figure S5. Pearson correlation of ChIP-qPCR results
between HMLE Twist, Snail and TGF-β1 cells.
Additional file 7: Figure S6. DNA methylation changes using bisulfite
sequencing in seven selected gene promoters following Twist-,
Snail- and TGF-β1-mediated EMT.
Additional file 8: Figure S7. DNA methylation changes using bisulfite
sequencing in seven selected gene promoters following Twist-, Snail-
and TGF-β1-mediated EMT.
Additional file 9: Figure S8. DNA methylation changes using bisulfite
sequencing in seven selected gene promoters following Twist-,
Snail- and TGF-β1-mediated EMT.
Additional file 10: Figure S9. DNA methylation and histone
modifications in HMLE Twist cells cultured as spheres. (A) Box-plot of
gene expression fold change (the bars represent 10% and 90% extreme)
for genes switching in HMLE vector cells from H3K4me3, H3K27me3,
bivalent or neither marks to other histone marks in HMLE Twist cells
cultured as spheres. (B) Correlation of methylation level of CpG sites
detected by DREAM in HMLE Twist cells cultured in a monolayer (2D)
(x-axis) and as spheres (MS) (y-axis). Green, CpG sites located in CGI; red,
CpG sites located outside CGI. (C) Switches of histone marks between
HMLE Twist cells cultured in a monolayer and as spheres.
Additional file 11: Figure S10. Expression of EMT-related transcription
factors after EZH2 knockdown. qRT-PCR performed for FOXC2 (A), SNAIL
(B) and ZEB1 (C) using RNA extracted from control and shEZH2 cells
showed that the expression level of those EMT-related transcription
factors remain unchanged.
Additional file 12: Figure S11. EZH1 knockdown in HMLE Twist cells.
(A) qRT-PCR expression of EZH1 in the indicated cell lines. (B) Knockdown
of EZH1 mediated by two independent shRNAs. EZH1 mRNA expression
was quantified by RT-PCR in the indicated cell lines. (C) Control and shEZH1
cells were grown in MS-promoting conditions and spheres greater in size
than 50 μm were counted after 10 days. A Student’s t-test was performed.
Additional file 13: Figure S12. Twist expression generated cells with
consistent levels of vimentin and Foxc2 expression. HMLE vector and
HMLE Twist cells were stained for vimentin (a) and for Foxc2 (b) along
with a DAPI co-stain.
Additional file 14: Figure S13. Twist, Snail and TGF-β1 expression
generated cells with consistently elevated levels of vimentin. HMLE
vector, HMLE Snail, HMLE Twist and HMLE TGF-β1 cells were stained for
vimentin along with a DAPI co-stain. The yellow arrow indicates a cell
without appreciable expression of vimentin.
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